Companies › Antengene Biologics
2 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology, Immunology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ATG-022 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma; Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced/Metastatic Solid Tumors | Sep 2027 |
| ATG-201 Bispecific T-cell engager (TCE) binding CD3 and CD19 | CD3, CD19 | Phase 1 | Systemic Lupus Erythematosus | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07327229 | ATG-022 | Phase 1 | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Oncology | Sep 2027 |
| NCT05718895 | ATG-022 | Phase 1 | Advanced/Metastatic Solid Tumors | Oncology | Dec 2027 |
| NCT07732309 | ATG-201 | Phase 1 | Systemic Lupus Erythematosus | Immunology | Dec 2028 |
| NCT07795346 | ATG-022 | Phase 3 | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Oncology | Dec 2029 |
Ganzhou Hemay Pharmaceutical Tanabe Pharma Hangzhou Sumgen Biotech Telios Pharma Molecure
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.